Loading stock data…
DAIICHI SANKYO COMPANY LIMITED (4568.T)
TSE¥2,751+15.50 (+0.57%)
Market ClosedLast close Sep 8
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Daiichi Sankyo Company, Limited in the Healthcare sector is trading at ¥2,751 with a market capitalization of $5.1T. Wall Street consensus targets ¥4,096 (16 analysts), implying a +48.9% move over the next 12 months. The stock is currently 34% below its 52-week high of ¥4,178, remaining 5.5% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +48.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (JPY) · Annual | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | ¥1.28T↓ | ¥1.60T↓ | ¥1.89T↓ | ¥2.12T |
| Gross Profit | ¥914.95B↓ | ¥1.19T↓ | ¥1.47T↑ | ¥1.45T |
| Operating Income | ¥120.58B↓ | ¥211.59B↓ | ¥331.93B↑ | ¥229.09B |
| Net Income | ¥109.19B↓ | ¥200.73B↓ | ¥295.76B↑ | ¥259.87B |
Peer Comparison
JNJUNHPFE
Fundamentals
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adeno...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥5.10T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
357.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.81%
Volume
Today's trading volume
4.92M
Recent News
AstraZeneca Says Breast Cancer Combo Approved in EU; Completes Acquisition of License for Lung Cancer Treatment
AstraZeneca (AZN) and Daiichi Sankyo's combination of Enhertu plus pertuzumab has been approved in t
European Indexes Mixed, Autos Rally
European stock indexes were mixed, with gains in autos and semiconductors unable to lift the lift the Europe-wide Stoxx 600 index.
Does Daiichi Sankyo Company (TSE:4568) Have A Bigger Oncology Opening In China And Europe?
Daiichi Sankyo Company (TSE:4568) has signed an exclusive commercialization agreement with Innovent Biologics for acute myeloid leukemia drug Vanflyta in China, following recent regulatory approval. Vanflyta targets a specific subset of acute myeloid leukemia patients and will be marketed in China, the world’s second largest pharmaceutical market. Datroway has received European Union approval as a first line treatment option for metastatic triple negative breast cancer. These oncology...
European Indexes Mostly Lower as Middle East Tensions Weigh
European markets mostly fell in opening trading as continued tensions in the Middle East weighed on sentiment.
Innovent and Daiichi Sankyo sign deal for Vanflyta in China
Under the agreement, Daiichi Sankyo handles development and supply, while Innovent Biologics leads commercialisation in China.